Chronic administration of risperidone to healthy rats: A behavioural and morphological study

Behavioural Brain Research

Volumn 205, Issue 2, 2009, Pages 488-498

  Castellano, O ^a,b   Moscoso, A ^a   Riolobos, A S ^a,b   Carro, J ^a,b   Arji, M ^a   Molina, V ^a,c   Lopez D E ^a,b   Sancho, C ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Active avoidance; Antipsychotic drugs; Behaviour; Immunohistochemistry; Oral administration; Prefrontal cortex; Prepulse inhibition

Indexed keywords

CALBINDIN; GLIAL FIBRILLARY ACIDIC PROTEIN; PARVALBUMIN; PROTEIN FOS; RISPERIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CELL COUNT; CONTROLLED STUDY; GROOMING; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLOGY; NONHUMAN; OPEN FIELD TEST; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; STARTLE REFLEX;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUDITORY PERCEPTION; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL COUNT; GLIAL FIBRILLARY ACIDIC PROTEIN; GROOMING; MALE; NEURONS; ORGAN SIZE; PARVALBUMINS; PROTO-ONCOGENE PROTEINS C-FOS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RISPERIDONE; STARTLE REACTION;

EID: 70349758087     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.08.002     Document Type: Article

References (113)

1. Aguilar M.A., Rodriguez-Arias M., Mari-Sanmillan M.I., and Minarro J. Effects of risperidone on conditioned avoidance responding in male mice. Behav Pharmacol 8 (1997) 669-676
2. Anselme P. The effect of exposure to drugs on the processing of natural rewards. Neurosci Biobehav Rev 33 3 (2009) 314-335
3. Arnt J., and Skarsfeldt T. Do novel neuroleptics have similar pharmacological haracteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
4. Audet M.C., Goulet S., and Dore F.Y. Repeated subchronic exposure to phencyclidine elicits excessive atypical grooming in rats. Behav Brain Res 167 (2006) 103-110
5. Barbalat G., Chambon V., Franck N., Koechlin E., and Farrer C. Organization of cognitive control within the lateral prefrontal cortex in schizophrenia. Arch Gen Psychiatry 66 4 (2009) 377-386
6. Bartzokis G., Lu P.H., Nuechterlein K.H., Gitlin M., Doi C., Edwards N., et al. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr Res 93 (2007) 13-22
7. Benes F.M., and Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25 1 (2001) 1-27
8. Benes F.M., Khan Y., Vincent S.L., and Wickramasinghe R. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 22 4 (1996) 338-349
9. Broderick P.A., Rahni D.N., and Zhou Y. Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior. Prog Neuropsychopharmacol Biol Psychiatry 27 6 (2003) 1037-1054
10. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 151 10 (1994) 1430-1436
11. Chana G., Landau S., Everall I., and Cotter D. Glial cell number and nuclear size in the mediodorsal thalamic nucleus (MDNT) in schizophrenia. Schizophr Res 102 1-3 (2008) 344-345
12. Conti L.H., Costill J.E., Flynn S., and Tayler J.E. Effects of a typical and an atypical antipsychotic on the disruption of prepulse inhibition caused by corticotropin-releasing factor and by rat strain. Behav Neurosci 119 4 (2005) 1052-1060
13. Crespo-Facorro B., Nopoulos P.C., Chemerinski E., Kim J.J., Andreasen N.C., and Magnotta V. Temporal pole morphology and psychopathology in males with schizophrenia. Psychiatry Res 132 2 (2004) 107-115
14. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 30 4 (2005) 765-774
15. Depoortere R., Perrault G., and Sanger D.J. Potentiation of prepulse inhibition of the startle reflex in rats: pharmacological evaluation of the procedure as a model for detecting antipsychotic activity. Psychopharmacology (Berl) 132 4 (1997) 366-374
16. Depoortere R., Perrault G., and Sanger D.J. Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav Pharmacol 8 4 (1997) 364-372
17. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 36 (1992) 61-89
18. Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Eur J Pharmacol 281 3 (1995) 241-250
19. Drago F., Contarino A., Marino R., Anzallo C., Valerio C., Rampello L., et al. Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats. Pharmacol Res 35 1 (1997) 17-25
20. Eyles D.W., McGrath J.J., and Reynolds G.P. Neuronal calcium-binding proteins and schizophrenia. Schizophr Res 57 1 (2002) 27-34
21. Faux S.F., Shenton M.E., McCarley R.W., Nestor P.G., Marcy B., and Ludwig A. Preservation of P300 event-related potential topographic asymmetries in schizophrenia with use of either linked-ear or nose reference sites. Electroencephalogr Clin Neurophysiol 75 5 (1990) 378-391
22. Feifel D., Melendez G., Priebe K., and Shilling P.D. The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res 181 2 (2007) 278-286
23. Ferrari F., Pelloni F., Filaferro M., and Giuliani D. Effect of the D2-autoreceptor agonist B-HT 958 on both spontaneous and ACTH-induced stretching, yawning and grooming in the rat. Life Sci 50 (1992) 1013-1019
24. Ferrari F., Pelloni F., and Giuliani D. The D2 agonist B-HT 920 potently antagonizes rat grooming. Pharmacol Res 25 2 (1992) 29-30
25. Fink-Jensen A., and Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett 182 1 (1994) 115-118
26. Gardner D.M., Woodman A.K., Grasswick L., and Kopala L. Drug and resource use evaluation of risperidone and olanzapine in inpatients with outpatient follow-up. Euro Neuropsychopharmacol 9 5 (1999) 277
27. Garver D.L., Holcomb J.A., and Christensen J.D. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry 58 1 (2005) 62-66
28. Genazzani A., Mauceri F., Valerio C., Nardo L., and Drago F. Effects of risperidone on motor and sexual activity in the rat. Pharmacol Res 22 Suppl. 1 (1990) 61-62
29. Gencer O., Emiroglu F.N., Miral S., Baykara B., Baykara A., and Dirik E. Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. Eur Child Adolesc Psychiatry 17 4 (2008) 217-225
30. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 2-3 (2001) 117-154
31. Gomes-Moscoso A, Castellano Benítez OJ, López García, DE. Administración crónica de Risperidona a ratas sanas. Efectos conductuales y morfológicos. In Gomes-Moscoso (Ediciones Universidad de Salamanca). Salamanca; 2009. ISBN: 978-84-613-1259-7.
32. Graham F.K. The more or less startling effects of weak prestimulation. Psychophysiology 12 3 (1975) 238
33. Green A.I., Lieberman J.A., Hamer R.M., Glick I.D., Gur R.E., Kahn R.S., et al., HGDH Study Group. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 86 1-3 (2006) 234-243
34. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96 10 (1988) 857-881
35. Haddad P.M., and Sharma S.G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21 (2007) 911-936
36. Hanada S., Mita T., Nishino N., and Tanaka C. [3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40 3 (1987) 259-266
37. Harvey P.D., Green M.F., Keefe R.S., and Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 65 3 (2004) 361-372
38. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry 32 7 (2008) 1758-1759
39. Iritani S., Kuroki N., Ikeda K., and Kazamatsuri H. Calbindin immunoreactivity in the hippocampal formation and neocortex of schizophrenics. Prog Neuropsychopharmacol Biol Psychiatry 23 3 (1999) 409-421
40. Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology 27 6 (2007) 604-608
41. Kapur S., Barsoum S.C., and Seeman P. Dopamine D2 receptor blockade by haloperidol: 3H-raclopride reveals much higher occupancy than EEDQ. Neuropsychopharmacology 23 5 (2000) 595-598
42. Karl T., Duffy L., O'brien E., Matsumoto I., and Dedova I. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behav Brain Res 171 2 (2006) 286-294
43. Karoutzou G., Emrich H.M., and Dietrich D.E. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 13 3 (2008) 245-260
44. Katsel P., Davis K.L., Li C., Tan W., Greenstein E., Kleiner Hoffman L.B., et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology 33 12 (2008) 2993-3009
45. Keefe R.S., Perkins D.O., Gu H., Zipursky R.B., Christensen B.K., and Lieberman J.A. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res 88 1-3 (2006) 26-35
46. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother 9 1 (2009) 9-31
47. Keith V.A., Mansbach R.S., and Geyer M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30 (1991) 557-566
48. Keshavan M.S., Bagwell W.W., Haas G.L., Sweeney J.A., Schooler N.R., and Pettegrew J.W. Changes in caudate volume with neuroleptic treatment. Lancet 344 8934 (1994) 1434
49. Kissling W., Glue P., Medori R., and Simpson S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol 22 8 (2007) 505-513
50. Kumari V., and Sharma T. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology (Berl) 162 2 (2002) 97-101
51. Kumari V., Soni W., and Sharma T. Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res 55 1-2 (2002) 139-146
52. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93 17 (1996) 9235-9240
53. Le Pen G., and Moreau J.L. Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 27 1 (2002) 1-11
54. Leumann L., Feldon J., Vollenweider F.X., and Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biol Psychiatry 52 7 (2002) 729-739
55. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6 4 (2005) 312-324
56. Lin E.J.D., Lee N.J., Slack K., Karl T., Duffy L., O'Brien E., et al. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology 51 7-8 (2006) 1129-1136
57. Lindström E., Eberhard J., and Levander S. Five-year follow-up during antipsychotic treatment: efficacy, safety, functional and social outcome. Acta Psychiatr Scand Suppl 435 (2007) 5-16
58. Lipska B.K., and Weinberger D.R. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 10 (1994) 199-205
59. MacGibbon G.A., Lawlor P.A., Bravo R., and Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Brain Res Mol Brain Res 23 1-2 (1994) 21-32
60. McCormick L., Decker L., Nopoulos P., Ho B.C., and Andreasen N. Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophr Res 80 1 (2005) 73-84
61. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 2 (1999) 233-255
62. Merchant K.M., and Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci USA 90 8 (1993) 3447-3451
63. Miller J.C. Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J Neurochem 54 4 (1990) 1453-1455
64. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10 1 (2005) 79-104
65. Molina V., Reig S., Sanz J., Palomo T., Benito C., Sánchez J., et al. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res 80 1 (2005) 61-71
66. Murphy C.A., and Feldon J. Interactions between environmental stimulation and antipsychotic drug effects on forebrain c-fos activation. Neuroscience 104 3 (2001) 717-730
67. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., and Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31 9 (2006) 1854-1863
68. Newton S.S., and Duman R.S. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 21 9 (2007) 715-725
69. Oka T., Hamamura T., Lee Y., Miyata S., Habara T., Endo S., et al. Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. Life Sci 76 2 (2004) 225-237
70. Oranje B., Van Oel C.J., Gispen-De Wied C.C., Verbaten M.N., and Kahn R.S. Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J Clin Psychopharmacol 22 4 (2002) 359-365
71. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates: the new coronal set-161 diagrams (2005), Academic Press, San Diego
72. Pratt J.A., Winchester C., Egerton A., Cochran S.M., and Morris B.J. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br J Pharmacol 153 1 (2008) 465-470
73. Pressler M., Nopoulos P., Ho B.C., and Andreasen N.C. Insular cortex abnormalities in schizophrenia: relationship to symptoms and typical neuroleptic exposure. Biol Psychiatry 57 4 (2005) 394-398
74. Puig M.V., Celada P., and Artigas F. Serotonergic control of prefrontal cortex. Rev Neurol 39 (2004) 539-547
75. Rainer M.K. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat 4 5 (2008) 919-927
76. Ravindran A.V., Bradbury C., McKay M., and da Silva T.L. Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. Expert Opin Pharmacother 8 (2007) 1693-1710
77. Ricci L.A., Connor D.F., Morrison R., and Melloni Jr. R.H. Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression. Biol Psychiatry 62 (2007) 218-225
78. Robertson G.S., and Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46 2 (1992) 315-328
79. Robertson G.S., Matsumura H., and Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271 2 (1994) 1058-1066
80. Rosengarten H., and Quartermain D. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats. Prog Neuropsychopharmacol Biol Psychiatry 26 6 (2002) 1047-1054
81. Rueter L.E., Ballard M.E., Gallagher K.B., Basso A.M., Curzon P., and Kohlhaas K.L. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl) 176 3-4 (2004) 312-319
82. Scherk H., and Falkai P. Effects of antipsychotics on brain structure. Curr Opin Psychiatry 19 2 (2006) 145-150
83. Selemon L.D., Lidow M.S., and Goldman-Rakic P.S. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol Psychiatry 46 2 (1999) 161-172
84. Semba J., Sakai M., Miyoshi R., Mataga N., Fukamauchi F., and Kito S. Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochem Int 29 4 (1996) 435-442
85. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology (Berl) 124 1-2 (1996) 126-133
86. Spruijt B.M., van Hooff J.A., and Gispen W.H. Ethology and neurobiology of grooming behavior. Physiol Rev 72 (1992) 825-852
87. Stanford S.C. The Open Field Test: reinventing the wheel. J Psychopharmacol 21 (2007) 134-135
88. Steffek A.E., McCullumsmith R.E., Haroutunian V., and Meador-Woodruff J.H. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 103 1-3 (2008) 71-82
89. Swerdlow N.R., Bakshi V., and Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279 (1996) 1290-1299
90. Szulc A. First and second generation antipsychotics and morphological and neurochemical brain changes in schizophrenia. Review of magnetic resonance imaging and proton spectroscopy findings. Psychiatr Pol 41 3 (2007) 329-338
91. Tan H.Y., Callicott J.H., and Weinberger D.R. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 17 1 (2007) 171-181
92. Tauscher-Wisniewski S., Kapur S., Tauscher J., Jones C., Daskalakis Z.J., Papatheodorou G., et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 63 11 (2002) 992-997
93. Terry Jr. A.V., Gearhart D.A., Mahadik S.P., Warsi S., Davis L.W., and Waller J.L. Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central α7 nicotinic Acetylcholine receptors. Neuroscience 136 (2005) 519-529
94. Terry Jr. A.V., Gearhart D.A., Mahadik S.P., Warsi S., and Waller J.L. Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain. Neuroscience 140 4 (2006) 1277-1287
95. Terry Jr. A.V., Gearhart D.A., Warner S.E., Zhang G., Bartlett M.G., Middlemore M.L., et al. Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience 146 3 (2007) 1316-1332
96. Terry Jr. A.V., Hill W.D., Parikh V., Evans D.R., Waller J.L., and Mahadik S.P. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Neuropsychopharmacology 28 2 (2003) 300-309
97. Terry Jr. A.V., and Mahadik S.P. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J Pharmacol Exp Ther 320 3 (2007) 961-968
98. Terry Jr. A.V., Warner S.E., Vandenhuerk L., Pillai A., Mahadik S.P., Zhang G., et al. Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats. Neuroscience 156 4 (2008) 1005-1016
99. Tseng KY, Chambers RA, Lipska BK. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia Behav Brain Res 2008; doi:10.1016/j.bbr.2008.11.039.
100. Van Wimersma Greidanus T.B., Maigret C., Torn M., Ronner E., Van der Kracht S., Van der Wee N.J., et al. Dopamine D-1 and D-2 receptor agonists and antagonists and neuropeptide-induced excessive grooming. Eur J Pharmacol 173 (1989) 227-231
101. Varty G.B., Bakshi V.P., and Geyer M.A. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20 (1999) 311-321
102. Varty G.B., and Higgins G.A. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berl) 122 1 (1995) 15-26
103. Verma V., Lim E.P., Han S.P., Nagarajah R., and Dawe G.S. Chronic high-dose haloperidol has qualitatively similar effects to risperidone and clozapine on immediate-early gene and tyrosine hydroxylase expression in the rat locus coeruleus but not medial prefrontal cortex. Neurosci Res 57 1 (2007) 17-28
104. Vollenweider F.X., Barro M., Csomor P.A., and Feldon J. Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol Psychiatry 60 6 (2006) 597-603
105. Vostrikov V.M., Uranova N.A., and Orlovskaya D.D. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 94 1-3 (2007) 273-280
106. Wadenberg M.L.G., Browning J.L., Young K.A., and Hicks P.B. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 68 3 (2001) 363-370
107. Wadenberg M.L.G., Soliman A., VanderSpek S.C., and Kapur S. Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25 (2001) 633-641
108. Wang H.D., Dunnavant F.D., Jarman T., and Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 29 7 (2004) 1230-1238
109. Wiley J.L. Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats. Euro J Pharmacol 578 2-3 (2008) 216-221
110. Wood J.D., Bonath F., Kumar S., Ross C.A., and Cunliffe V.T. Disrupted-in-schizophrenia 1 and neuregulin 1 are required for the specification of oligodendrocytes and neurones in the zebrafish brain. Hum Mol Genet 18 3 (2009) 391-404
111. Wynn J.K., Green M.F., Sprock J., Light G.A., Widmark C., Reist C., et al. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 95 1-3 (2007) 134-142
112. Zhang Z.J., and Reynolds G.P. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 55 1-2 (2002) 1-10
113. Zuo D.Y., Cao Y., Zhang L., Wang H.F., and Wu Y.L. Effects of acute and chronic administration of MK-801 on c-Fos protein expression in mice brain regions implicated in schizophrenia with or without clozapine. Prog Neuropsychopharmacol Biol Psychiatry 33 2 (2009) 290-295